U.S. markets closed

Aptevo Therapeutics Inc. (APVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
25.86+0.29 (+1.13%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close25.57
Open25.52
Bid20.20 x 1800
Ask27.50 x 900
Day's Range24.45 - 26.36
52 Week Range3.44 - 60.00
Volume20,177
Avg. Volume59,150
Market Cap115.062M
Beta (5Y Monthly)7.33
PE Ratio (TTM)N/A
EPS (TTM)-5.24
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting

    SEATTLE, WA/ ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021.

  • ACCESSWIRE

    Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update

    Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 OngoingCompletes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Agreement SEATTLE, WA / ACCESSWIRE / March 31, 2021 / Aptevo Therapeutics Inc.

  • ACCESSWIRE

    Aptevo Confirms Receipt of Nominations and Proposal Notice

    Stockholders Are Not Required to Take Any Action at this TimeSEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today confirmed that it has received a notice from Tang Capital Partners, LP ("TCP") that TCP intends to nominate two candidates to stand for election to the Board of Directors and submit an advisory stockholder proposal at the Company's 2021 Annual Meeting of Stockholders.